Belite Bio (BLTE) to Release Earnings on Tuesday

Belite Bio (NASDAQ:BLTE) is scheduled to be announcing its earnings results after the market closes on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.

Belite Bio (NASDAQ:BLTE) last posted its quarterly earnings data on Monday, March 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.11. On average, analysts expect Belite Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Belite Bio Trading Down 0.9 %

Shares of BLTE stock opened at $42.80 on Thursday. The business’s 50 day moving average is $40.62 and its two-hundred day moving average is $42.15. Belite Bio has a twelve month low of $11.00 and a twelve month high of $48.60. The company has a market capitalization of $1.25 billion, a P/E ratio of -34.52 and a beta of -1.52.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $59.00 target price on shares of Belite Bio in a research note on Friday, March 22nd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $44.83.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.